Tech Company Financing Transactions
Carmot Therapeutics Funding Round
On 5/25/2023, Carmot Therapeutics secured $150 million in Series E financing from Deep Track Capital, 5AM Ventures and Franklin Templeton.
Transaction Overview
Company Name
Announced On
5/25/2023
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series E
Investors
Proceeds Purpose
The company will use the funds to Advance its Pipeline of Treatments for Obesity and Diabetes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Carmot Therapeutics develops drugs to treat inflammatory, metabolic and neurological diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stig Hansen
Chief Medical Officer
Allan Gordon
VP - Bus. Development
James Watson
Browse more venture capital transactions:
Prev: 5/25/2023: Dock Health venture capital transaction
Next: 5/25/2023: Vias Campus Management venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs